Get the Stockscreener App
10.75
1.83%
-0.20
Urogen Pharma Ltd stock is traded at $10.75, with a volume of 88,048.
It is down -1.83% in the last 24 hours and down -2.98% over the past month.
UroGen Pharma Ltd is a clinical-stage biotechnology firm specializing in innovative solutions for urothelial and specialty cancers. The company has developed RTGel reverse-thermal hydrogel, a proprietary technology enhancing the therapeutic profiles of existing drugs by enabling sustained release. Their flagship product, Jelmyto (mitomycin) for pyelocalyceal solution, along with investigational candidate UGN-102 (mitomycin) for intravesical solution, targets non-surgical tumor ablation in forms of non-muscle invasive urothelial cancer. Additionally, their immuno-uro-oncology pipeline includes UGN-301 (zalifrelimab), an anti-CTLA-4 antibody, intended for both monotherapy and combination therapy. Revenue is generated from product sales.
See More
Previous Close:
$10.95
Open:
$10.91
24h Volume:
88,048
Relative Volume:
0.23
Market Cap:
$462.08M
Revenue:
$82.71M
Net Income/Loss:
$-102.24M
P/E Ratio:
-2.9292
EPS:
-3.67
Net Cash Flow:
$-76.57M
1W Performance:
-2.36%
1M Performance:
-2.98%
6M Performance:
-25.71%
1Y Performance:
-32.90%
1-Day Range:
$10.57
$10.92
1-Week Range:
$10.57
$11.87
52-Week Range:
$9.78
$20.70
Urogen Pharma Ltd Stock (URGN) Company Profile
Name
Urogen Pharma Ltd
Sector
Industry
Phone
972 9 770 7601
Address
9 HA'TA'ASIYA ST, RA'ANANA
Compare URGN with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
URGN
Urogen Pharma Ltd
|
10.75 | 462.08M | 82.71M | -102.24M | -76.57M | -3.67 |
|
VRTX
Vertex Pharmaceuticals Inc
|
474.46 | 123.91B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
716.63 | 78.94B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
651.17 | 39.98B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
275.24 | 35.89B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
118.75 | 28.75B | 3.30B | -501.07M | 1.03B | -2.1146 |
Urogen Pharma Ltd Stock (URGN) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Aug-22-24 | Initiated | Guggenheim | Buy |
| Feb-08-23 | Downgrade | Jefferies | Buy → Hold |
| Apr-27-22 | Initiated | Berenberg | Buy |
| Apr-16-20 | Reiterated | H.C. Wainwright | Buy |
| Apr-13-20 | Reiterated | H.C. Wainwright | Buy |
| Jan-09-20 | Initiated | National Securities | Neutral |
| May-30-19 | Initiated | JP Morgan | Neutral |
| May-29-19 | Initiated | Goldman | Neutral |
| Jan-29-19 | Initiated | H.C. Wainwright | Buy |
| Nov-08-18 | Resumed | Jefferies | Buy |
| Apr-04-18 | Upgrade | Raymond James | Mkt Perform → Outperform |
| Jan-02-18 | Initiated | Ladenburg Thalmann | Buy |
| Nov-15-17 | Reiterated | Oppenheimer | Outperform |
| Nov-15-17 | Downgrade | Raymond James | Outperform → Mkt Perform |
View All
Urogen Pharma Ltd Stock (URGN) Latest News
Insider Selling: UroGen Pharma Ltd. (NASDAQ:URGN) General Counsel Sells $82,202.06 in Stock - Armenian Reporter
UroGen Pharma Ltd. (NASDAQ:URGN) Insider Mark Schoenberg Sells 4,551 Shares - MarketBeat
UroGen Pharma Ltd. (NASDAQ:URGN) General Counsel Jason Drew Smith Sells 7,379 Shares - MarketBeat
UroGen Pharma's chief medical officer sells shares worth $50,698 - MSN
Urogen Pharma's general counsel sells $82,202 in shares - MSN
Urogen Pharma's general counsel sells $82,202 in shares By Investing.com - Investing.com South Africa
URGN (UroGen Pharma) Revenue per Share : $2.39 (TTM As of Sep. 2024) - GuruFocus.com
URGNUroGen Pharma Ltd. Ordinary Shares Latest Stock News & Market Updates - StockTitan
URGN (UroGen Pharma) EPS without NRI : $-2.60 (TTM As of Sep. 2024) - GuruFocus.com
UroGen: Upcoming PDUFA, Some Concerns Remain (NASDAQ:URGN) - Seeking Alpha
UroGen Pharma to Present at Upcoming Investor Conferences - The Bakersfield Californian
UroGen Takes Center Stage: Double Feature at Elite Healthcare Investment Forums - StockTitan
JPMorgan Chase & Co. Has $864,000 Stock Holdings in UroGen Pharma Ltd. (NASDAQ:URGN) - Defense World
JPMorgan Chase & Co. Grows Stock Position in UroGen Pharma Ltd. (NASDAQ:URGN) - MarketBeat
UroGen Pharma’s (URGN) Buy Rating Reiterated at D. Boral Capital - Defense World
UroGen Pharma Ltd. (NASDAQ:URGN) Receives $43.70 Average Price Target from Analysts - MarketBeat
UroGen Pharma Ltd. (NASDAQ:URGN) Receives Consensus Rating of “Buy” from Brokerages - Defense World
UroGen Pharma's (URGN) "Buy" Rating Reaffirmed at D. Boral Capital - MarketBeat
JELMYTO shows promise in long-term cancer treatment study By Investing.com - Investing.com Australia
JELMYTO shows promise in long-term cancer treatment study - Investing.com
New Real-World Durability of Response Data for JELMYTO Reports 68% Recurrence-Free Survival Rate (RFS) at Three Years Across a Broad Patient Population with Low-Grade Upper Tract Urothelial Cancer (LG-UTUC) - Yahoo Finance
D. Boral Capital Reiterates Buy Rating for UroGen Pharma (NASDAQ:URGN) - Defense World
Bladder Cancer Clinical and Non-Clinical Studies, Key - openPR
Barclays PLC Increases Stake in UroGen Pharma Ltd. (NASDAQ:URGN) - Defense World
UroGen Pharma Ltd. (NASDAQ:URGN) Shares Purchased by Barclays PLC - MarketBeat
UroGen Pharma Reveals Promising Developments in Latest 8-K Filing - Defense World
UroGen Pharma (NASDAQ:URGN) Given "Buy" Rating at D. Boral Capital - MarketBeat
UroGen's UGN-102 shows high response in bladder cancer study By Investing.com - Investing.com South Africa
ENVISION Trial Results Published in the February Issue of The Journal of Urology Highlight UGN-102 Achievement of 82.3% Duration of Response at 12 Months Paving the Way for the Potential First FDA-Approved Treatment for LG-IR-NMIBC in June 2025 - BioSpace
UroGen's UGN-102 shows high response in bladder cancer study - Investing.com
Further weakness as UroGen Pharma (NASDAQ:URGN) drops 10% this week, taking five-year losses to 67% - Simply Wall St
UroGen Pharma Highlights RTGel® Platform and Growth Plans - TipRanks
Jane Street Group LLC Sells 8,198 Shares of UroGen Pharma Ltd. (NASDAQ:URGN) - Defense World
How To Trade (URGN) - Stock Traders Daily
Geode Capital Management LLC Purchases 34,248 Shares of UroGen Pharma Ltd. (NASDAQ:URGN) - Defense World
Barclays PLC Has $759,000 Holdings in UroGen Pharma Ltd. (NASDAQ:URGN) - Defense World
Barclays PLC Boosts Holdings in UroGen Pharma Ltd. (NASDAQ:URGN) - MarketBeat
Breakeven On The Horizon For UroGen Pharma Ltd. (NASDAQ:URGN) - Yahoo Finance
UroGen Pharma Ltd. (NASDAQ:URGN) Receives $43.70 Consensus Target Price from Brokerages - MarketBeat
UroGen Pharma Ltd. (NASDAQ:URGN) Receives Average Recommendation of “Buy” from Brokerages - Defense World
UroGen Pharma Ltd. (NASDAQ:URGN) Shares Purchased by State Street Corp - Defense World
Fmr LLC Buys 19,670 Shares of UroGen Pharma Ltd. (NASDAQ:URGN) - Defense World
URGN stock touches 52-week low at $10.6 amid market challenges - Investing.com Canada
URGN stock touches 52-week low at $10.6 amid market challenges By Investing.com - Investing.com South Africa
BNP Paribas Financial Markets Grows Stake in UroGen Pharma Ltd. (NASDAQ:URGN) - Defense World
Charles Schwab Investment Management Inc. Increases Stock Position in UroGen Pharma Ltd. (NASDAQ:URGN) - Defense World
Analysts Set UroGen Pharma Ltd. (NASDAQ:URGN) PT at $43.70 - MarketBeat
UroGen Pharma (NASDAQ:URGN) Given Buy Rating at D. Boral Capital - MarketBeat
Point72 Asset Management L.P. Cuts Position in UroGen Pharma Ltd. (NASDAQ:URGN) - MarketBeat
(URGN) Investment Report - Stock Traders Daily
UroGen Pharma Grants 112,800 RSUs to Expand Commercial Team for Jelmyto Rollout - StockTitan
Urogen Pharma Ltd Stock (URGN) Financials Data
Revenue
Net Income
Cash Flow
EPS
Urogen Pharma Ltd Stock (URGN) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Smith Jason Drew | General Counsel |
Jan 31 '25 |
Sale |
11.14 |
7,379 |
82,202 |
26,468 |
| Schoenberg Mark | Chief Medical Officer |
Sep 09 '24 |
Sale |
13.08 |
859 |
11,236 |
145,091 |
| Smith Jason Drew | General Counsel |
Sep 09 '24 |
Sale |
13.08 |
1,521 |
19,895 |
25,226 |
0.51%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):